Emiliano Menna
Research Subjects
Emiliano Menna has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Marchioni
Hospital Alemán, CABA, Buenos Aires, Argentina
1 shared publication - Augusto Ferreyra Camacho
CABA, Hospital Universitario Austral, Buenos Aires, Argentina
1 shared publication - Federico Cayol
Sección de Oncología Clínica, Hospital Italiano de Buenos Aires
1 shared publication Geraldine Gueron
CONICET-Universidad de Buenos Aires, Instituto de Química Biológica de la Facultad de Ciencias Exactas y Naturales (IQUIBICEN), CABA, Buenos Aires, Argentina
1 shared publication- Gonzalo Taetti
Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” (CEMIC), CABA, Buenos Aires, Argentina
1 shared publication Hernan Cutuli
Entre Ríos, Hospital Sirio Libanes, Buenos Aires, Argentina
1 shared publication
Latest Publications
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Genomic Landscape of Metastatic Urothelial Cancer in a Multicenter Cohort From Argentina
PURPOSE: The genomic landscape of advanced urothelial carcinoma (aUC) has enabled the development of targeted therapies; however, real-world data from Latin America remain limited. MATERIALS AND METHODS: We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT). RESULTS: A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification. CONCLUSION: A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.
- 1 August 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (8)
Genomic Landscape of Metastatic Urothelial Cancer in a Multicenter Cohort From Argentina
PURPOSE: The genomic landscape of advanced urothelial carcinoma (aUC) has enabled the development of targeted therapies; however, real-world data from Latin America remain limited. MATERIALS AND METHODS: We conducted a multicenter retrospective study including patients with aUC who underwent next-generation sequencing on tumor tissue. Molecular alterations were classified according to the European Society for Medical Oncology (ESMO) Scale for Clinical Actionability of Molecular Targets (ESCAT). RESULTS: A total of 107 patients were included. Overall, 68 patients (63.6%) harbored at least one potentially actionable molecular alteration. Among these, 34 patients (31.8%) exhibited ESCAT level I alterations, most commonly involving FGFR3 mutations/fusions and ERBB2 amplification. CONCLUSION: A clinically meaningful proportion of Argentine patients with aUC harbor ESCAT level I actionable alterations, supporting the incorporation of routine genomic profiling into clinical practice.